Eczema Tablets and Injections: What a Head-to-Head Trial Compared

DOCTOR'S NOTES · ECZEMA EVIDENCE

For some people, moderate-to-severe eczema remains disruptive despite treatment. A dermatologist may discuss medicines taken by mouth or by injection. Their risks, eligibility and monitoring differ, so the right choice is personal.

What did the Level Up trial measure?

A randomized head-to-head study compared oral upadacitinib with injected dupilumab in adolescents and adults with moderate-to-severe atopic dermatitis who had an inadequate response to systemic therapy or for whom it was inadvisable. It was open label, while efficacy assessors were blinded.

At week 16, 19.9% assigned to upadacitinib and 8.9% assigned to dupilumab met a demanding combined target: at least 90% improvement in EASI and an itch score of zero or one. Other meaningful improvements were not counted in that combined number. Study dosing, follow-up and eligibility matter; it is not proof that one treatment is best for every patient.

Safety and daily logistics

The upadacitinib label carries boxed warnings including serious infections, cancer, major cardiovascular events and thrombosis. The dupilumab label discusses hypersensitivity and eye-related reactions. Ask about medical history, infection screening, blood tests where appropriate, vaccine planning, injection training and the cost of treatment. Do not switch or combine medications without the prescriber.

Our introduction to dupilumab research explains its separate trials. For interpreting the skin score, see what EASI-75 means; EASI-90 is a stricter improvement threshold.

What does a combined endpoint leave out?

A person could have a major improvement in visible eczema but still report itch above the study's strict threshold. Another might have less itch without a 90% skin-score improvement. Neither would meet this combined endpoint. The result is useful for comparing the chance of reaching both targets under the study conditions, but it should not be described as the percentage of people who benefited at all.

Open-label treatment also matters: participants and treating staff knew which medicine was being given, even though efficacy assessors were blinded. That design has different strengths and limitations from a fully blinded placebo comparison. The study's dose-adjustment strategy is another reason not to turn a headline into a prescription choice.

Bring a list of previous prescriptions, how they were used and why they stopped. A medicine that was never tolerated, one that was hard to obtain and one that was ineffective are different parts of the history. The next plan should address that difference.

What if convenience points in a different direction?

A daily tablet and an injection create different routines, but convenience is only one part of the decision. Tell the prescriber if shift work, travel, needle concerns or laboratory access would make a plan hard to follow. Ask which of those barriers can be addressed and which may affect the choice. Do not assume that a tablet's route makes it lower risk, or that an injection automatically works more slowly for every outcome. The comparison applies to the studied regimens and people; your medical history still has to be assessed separately.

Follow the related evidence

Evidence for a different injected medicine appears in the lebrikizumab NEJM trials. The nemolizumab ARCADIA studies show another approach and another accompanying treatment context.

Prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Educational information supports a discussion with a qualified clinician; it does not diagnose or prescribe for an individual. The AI-created product image is an editorial illustration, not a patient photograph or a clinical result.